Galectin Therapeutics Inc.

As of June 30, 2026, Galectin Therapeutics Inc. carries a market capitalization of 266.57M, placing it among publicly traded companies globally. Its enterprise value stands at 377.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Galectin Therapeutics Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Galectin Therapeutics Inc. has 66.31M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Galectin Therapeutics Inc. maintains a current ratio of 0.10, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -100.66, indicating conservative leverage, while an interest coverage ratio of -2.01 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -183.01, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 10.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Galectin Therapeutics Inc.'s stock has declined approximately 27.96% over the past 52 weeks. The 50-day moving average sits at 3.38, while the 200-day moving average is 2.79.

Over the twelve months ended June 30, 2026, Galectin Therapeutics Inc. generated - - in revenue and converted that into -24.37M in net income, yielding earnings per share of -0.37. EBITDA reached -13.62M, while operating income came in at -13.67M.

As of June 30, 2026, Galectin Therapeutics Inc. holds 11.61M in cash and equivalents against 120.58M in total debt, resulting in a net debt position of 108.92M. Total book value stands at -121.71M, with working capital of -119.88M providing operational flexibility.

Galectin Therapeutics Inc. produced -13.91M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of 0.66 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -5.30: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.05, meaning Galectin Therapeutics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Galectin Therapeutics Inc.'s most recent stock split took place on March 23, 2012 with a 6:1 split ratio.

As of June 30, 2026, Galectin Therapeutics Inc. has an Altman Z-Score of -55.55, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.